Sector Experts

Subscribe to
Streetwise Reports

Ask this Expert

Companies Commented On

  • Agenus Inc.
  • Alnylam Pharmaceuticals Inc.
  • Ariad Pharmaceuticals Inc.
  • Athersys Inc.
  • Baxter International Inc.
  • bluebird bio Inc.
  • Celgene Corp.
  • Celsion Corp.
  • Cesca Therapeutics Inc.
  • CTI BioPharma
  • Curis Inc.
  • Dendreon Corp.
  • Fate Therapeutics Inc.
  • Galectin Therapeutics Inc.
  • GenVec Inc.
  • Gilead Sciences Inc.
  • Idera Pharmaceuticals
  • Incyte Corp.
  • Inovio Pharmaceuticals Inc.
  • International Stem Cell Corp.
  • Isis Pharmaceuticals Inc.
  • Keryx Biopharmaceuticals Inc.
  • La Jolla Pharmaceutical Co.
  • Lion Biotechnologies Inc.
  • Mesoblast Ltd.
  • NeoStem Inc.
  • Neuralstem Inc.
  • Novartis AG
  • OncoMed Pharmaceuticals Inc.
  • OncoSec Medical Inc.
  • Oncothyreon Inc.
  • OXiGENE Inc.
  • Pharmacyclics Inc.
  • Prosensa Holding N.V.
  • Roche Holding AG
  • RXi Pharmaceuticals Corp.
  • Sanofi SA
  • Sarepta Therapeutics Inc.
  • Spectrum Pharmaceuticals Inc.
  • Stemline Therapeutics Inc.
  • Tekmira Pharmaceuticals Inc.
  • TG Therapeutics Inc.
  • Verastem Inc.
  • Vical Inc.

Reni Benjamin

H.C. Wainwright & Co.

Image: Reni Benjamin

Dr. Reni Benjamin is a managing director and equity research analyst at H.C. Wainwright & Co. His expertise and coverage focuses on companies in the oncology and stem cell sectors. Benjamin has been ranked among the top analysts for recommendation performance and earnings accuracy by StarMine, has been cited in a variety of sources including The Wall Street Journal, Bloomberg Businessweek, Financial Times and Smart Money, and has made appearances on Bloomberg television/radio and CNBC. He authored a chapter in ôThe Delivery of Regenerative Medicines and Their Impact on Healthcare,ö has presented at various regional and international conferences, and has been published in peer-reviewed journals. He currently serves on the UAB School of Health Professions' Deans Advisory Board. Prior to joining H.C. Wainwright, Benjamin was a managing director and senior biotechnology analyst at both Burrill Securities and Rodman & Renshaw. He was also an associate analyst at Needham and Company. Benjamin earned his doctorate from the University of Alabama at Birmingham in biochemistry and molecular genetics by discovering and characterizing a novel gene implicated in germ cell development. He earned a bachelor's degree in biology from Allegheny College.




Recent Interviews

Turnaround Stories Lead Reni Benjamin's Biotech Front-Runners (7/10/14) The biotech bull market is not over. That's the judgment of Reni Benjamin of H.C. Wainwright & Co., who predicts high quality data from a broad range of small- and mid-cap biotechs will move shares higher during the summer and especially in the fall. In this interview with The Life Sciences Report, Benjamin showcases names with powerful platforms and market winds to their backs, which he believes could vigorously multiply investor capital over the next 12ľ18 months.

Regenerative Medicine Finally Gets Some Respect: Reni Benjamin (2/11/14) Of the many themes that propelled the biotech sector to record returns in 2013, regenerative medicine and therapeutics targeting cancer were front and center. In this interview with The Life Sciences Report, Reni Benjamin, managing director and equity research analyst at H.C. Wainwright & Co., talks about two companies with impending catalysts that play on these themes, and offers his take on the prospects for the regenerative medicine sector going forward.

Shopping for Biotech Growth Names: Reni Benjamin (12/12/13) Get ready for a bonanza of biotech names. Managing Director and Equity Research Analyst Reni "Ren" Benjamin is a new arrival at H.C. Wainwright & Co., and he's busy doing diligence on a lot of stocks. Along with three Buy-rated biotechs he's already initiated coverage on, Benjamin brought The Life Sciences Report a bonus package of names that could fatten investors' portfolios. Backed by Benjamin's extensive industry knowledge, this long shopping list includes companies poised to make drug development history.

Recent Quotes

"CUR's forward progress of the NSI-556 trial for SCI is welcome news." (10/13/14) Neuralstem Inc. - Reni Benjamin, H.C. Wainwright & Co. Moreá>

"CUR's NSI-566 could be a treatment capable of producing long-lasting and durable responses." (9/23/14) Neuralstem Inc. - Reni Benjamin, H.C. Wainwright & Co. Moreá>

"RXII's study data showed statistically significant improvement." (9/11/14) RXi Pharmaceuticals Corp. - Reni Benjamin, H.C. Wainwright & Co. Moreá>

"We are initiating coverage on CUR." (9/8/14) Neuralstem Inc. - Reni Benjamin, H.C. Wainwright & Co. Moreá>

"RXII could report preliminary data over the next four to six months." (8/15/14) RXi Pharmaceuticals Corp. - Reni Benjamin, H.C. Wainwright & Co. Moreá>

"KOOL's expanded collaboration with Fortis is excellent news." (8/5/14) Cesca Therapeutics Inc. - Reni Benjamin, H.C. Wainwright & Co. Moreá>

"KOOL's expanded collaboration with Fortis is excellent news." (8/5/14) Cesca Therapeutics Inc. - Reni Benjamin, H.C. Wainwright & Co. Moreá>

"RXII represents an undervalued player in the RNA interference space." (7/31/14) RXi Pharmaceuticals Corp. - Reni Benjamin, H.C. Wainwright & Co. Moreá>

more comments

"We feel RXII has largely been ignored by investors, but has potential." (7/10/14) RXi Pharmaceuticals Corp. - The Life Sciences Report Interview with Reni Benjamin Moreá>

"KOOL is an undervalued player with significant long-term upside." (7/8/14) Cesca Therapeutics Inc. - Reni Benjamin, H.C. Wainwright & Co. Moreá>

"We are initiating coverage on KOOL with a Buy rating." (6/26/14) Cesca Therapeutics Inc. - Reni Benjamin, H.C. Wainwright & Co. Moreá>

"RXII is an undervalued player with significant upside long term." (5/16/14) RXi Pharmaceuticals Corp. - Reni Benjamin, H.C. Wainwright & Co. Moreá>

"We are initiating coverage on RXII with a Buy rating." (5/5/14) RXi Pharmaceuticals Corp. - Reni Benjamin, H.C. Wainwright & Co. Moreá>

"KOOL has the potential to make a significant mark in the regenerative medicine space." (2/11/14) Cesca Therapeutics Inc. - The Life Sciences Report Interview with Reni Benjamin Moreá>

"Investors should definitely take a look at KOOL." (12/12/13) Cesca Therapeutics Inc. - The Life Science Report Interview with Reni Benjamin Moreá>

"MSB has a 1,700-patient phase 3 study in progress, evaluating Revascor in congestive heart failureŚclearly a big market." (12/12/13) Mesoblast Ltd. - The Life Sciences Report Interview with Reni Benjamin Moreá>

"CUR is making significant strides in the regenerative medicine space." (12/12/13) Neuralstem Inc. - The Life Sciences Report Interview with Reni Benjamin Moreá>

"RXII is one of the key players in the RNAi space that I think show significant promise." (12/12/13) RXi Pharmaceuticals Corp. - The Life Sciences Report Interview with Reni Benjamin Moreá>

"INO is developing and advancing DNA vaccines with a twist." (12/11/13) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Reni Benjamin Moreá>

fewer comments


Due to permission requirements, not all quotes are shown.